Table 2. Adverse events (N=12).

Toxicity	Grade 2 [%]	Grade 3 [%]	Grade 4 [%]	Total [%]
Alkaline phosphatase increased	1 [8]	0	0	1 [8]
Anemia	5 [42]	0	0	5 [42]
Anorexia	1 [8]	0	0	1 [8]
Atrial fibrillation	1 [8]	0	0	1 [8]
Blood bilirubin increased	0	1 [8]	0	1 [8]
Cough	1 [8]	0	0	1 [8]
Dizziness	1 [8]	0	0	1 [8]
Dyspnea	1 [8]	0	0	1 [8]
Edema limbs	2 [17]	0	0	2 [17]
Fatigue	1 [8]	1 [8]	0	2 [17]
Hyperglycemia	0	2 [17]	0	2 [17]
Hyperkalemia	1 [8]	0	0	1 [8]
Hypertension	0	1 [8]	0	1 [8]
Hypoalbuminemia	1 [8]	0	0	1 [8]
Hyponatremia	0	1 [8]	0	1 [8]
Lymphocyte count decreased	0	3 [25]	0	3 [25]
Mucositis oral	1 [8]	1 [8]	0	2 [17]
Nausea	0	1 [8]	0	1 [8]
Neutrophil count decreased	2 [17]	0	0	2 [17]
Non-cardiac chest pain	1 [8]	0	0	1 [8]
Pericardial effusion	0	0	1 [8]	1 [8]
Platelet count decreased	1 [8]	0	0	1 [8]
Pleural effusion	2 [17]	0	0	2 [17]
Rash maculo-papular	1 [8]	0	0	1 [8]
White blood cell decreased	1 [8]	1 [8]	0	2 [17]